Résultats du Concours 2026 de subventions pour l’innovation en recherche du PRDTC

Le PRDTC est ravi d’annoncer les résultats du Concours 2026 de subventions pour l’innovation en recherche, rendu possible grâce à des partenariats avec diverses organisations. Nous sommes fiers de présenter tous les projets innovants qui ont été financés dans le cadre du concours de cette année.

Nous tenons à féliciter chaleureusement Dre. Karen Sherwood et Dr. Tom Blydt-Hansen et leur équipe pour avoir reçu la bourse d’innovation en recherche PRDTC KFOC. Nous leur souhaitons tout le succès possible dans la réalisation de leur projet novateur!

« The Kidney Foundation of Canada is excited to support this work which could see immunosuppression after transplantation as a thing of the past. While transplantation can provide a new outlook on life for many kidney patients, it is often accompanied by a lifelong complications resultant from the requirement to take medications to suppress the host immune system. Innovation that could contribute to the reduction of immunosuppressive medications, have the potential to result in meaningful change for the post transplant community, and increase the potential for transplant as a treatment in a larger percentage of the population. »

Bourse d’innovation en recherche PRDTC KFOC: Dre. Karen Sherwood et Dr. Tom Blydt-Hansen

Titre du Projet: Precision Immune Genomics in Pediatric Kidney Transplantation: A Novel Application of Nanopore Adaptive Sampling for integrated genomic Risk Stratification

Affiliation principale : University of British Columbia

Thème: 4 – Un système immunitaire adapté à chaque patient

Résumé (en anglais):

Kidney transplantation gives children with kidney failure the opportunity for a longer, healthier life, but every child’s immune system is different. Some children develop early rejection or persistent inflammation that damages their transplanted kidney, while others thrive on standard treatment. Today, we lack the tools to predict before transplant which children carry an inherently higher immune risk, leaving clinicians unable to tailor immunosuppression to the individual child.

Answering this challenge sits at the heart of CDTRP’s vision: to tailor an optimal immune system for each patient. This study will examine 42 variations across 28 immune-related genes in DNA samples from 200 pediatric kidney transplant recipients in British Columbia. Each gene variant has been individually linked to rejection or graft failure in other studies; however, we propose to understand how they interact in aggregate to shape each child’s net immune response after transplantation.

Using Oxford Nanopore adaptive sampling, a novel sequencing strategy, we will build individual genetic risk profiles and connect them to real clinical outcomes: kidney biopsies, urine inflammatory markers, and long-term graft survival. Machine learning will identify which combinations of variants best predict early rejection, allograft inflammation, and graft failure.

The result will be a personalized pre-transplant immune risk score to guide donor selection, monitoring intensity, and immunosuppression dosing for each child. Patient, family, and donor partners are embedded throughout this work, co-developing how findings are interpreted and communicated, and ensuring that this genetic risk tool is meaningful, trustworthy, and ready for real-world clinical implementation. This precision approach directly supports the CDTRP mission of moving transplant medicine from reactive to proactive, individualized care.